Episode Details

In this episode,Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections caused by NDM-producing Enterobacterales, including: 

• Ambler classification of β-lactamases
• Mechanisms of resistance
• 2023 IDSA guidance recommendations
• The latest clinical data by antimicrobial regimen:
• Ceftazidime/avibactam and aztreonam
• Cefiderocol
• Investigational aztreonam/avibactam
• Clinical case of NDM-producing E. coli with pan-β-lactam resistance

Program Director:

Trevor Van Schooneveld, MD, FSHEA, FACP 
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska

Faculty:

Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland 
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine 
Atlanta, Georgia

Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Follow along with a downloadable slideset at: 
https://bit.ly/476v2wI

Link to full program:
https://bit.ly/40HyvPy

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.